Able Labs Recall Of All Marketed Products Boosts 2005 Drug Recall Total
Executive Summary
Generic drug manufacturer Able Laboratories' recall of all of its marketed products following an FDA GMP inspection accounted for half of the substantial rise of products recalled during 2005 versus the previous year
You may also be interested in...
COVID To GLP-1: Catalent Plants Ride With Novo To Next Public Health Crisis
A complex transformation is underway as client proposes to acquire CDMO facilities that vaccinated the world against the COVID-19 pandemic for pivot to the obesity epidemic.
From COVID Cliff To GLP-1 Ramp: Novo Takes Catalent Plants For Next Public Health Crisis
A complex transformation is underway as client proposes to acquire CDMO facilities that vaccinated the world against the COVID-19 pandemic for pivot to the obesity epidemic.
FDA Cites Able For Failing To Reject Out-Of-Specification Drugs, Altering Data
Able Labs routinely failed to reject drugs that did not meet established standards, specifications and quality control criteria, according to FDA inspectional observations included in a "Form 483" report